Biosimilars Governmental Regulation

Question 1

Private healthcare

Answer 1

Is highly unregulated

SHORT TERM GAIN WITH LONG TERM PAIN

Question 2

Highest selling drugs

Answer 2

Adalimumab which is a biologic and makes a revuene estimated of 20bn dollars a year.

Question 3

Drug prescription prices in America are ridiclously high

Answer 3

People soemtimes skip doses in order to afford their medicines which is not ideal.
This is morally repugnant but this is due to the high unregulation.
Richard Gonzalez’s multi-million pound bonus was due to the sale of Humira, therefore people cannot have this medication

Question 4

Inuslin price

Answer 4

Has increased 6 fold per vial.

Question 5

Patent increase

Answer 5

The drug that was for one original indication can have a further 20 years which can be achieved by a simple change of indication

Question 6

Ban on kidney cancer drugs lifted

Answer 6

Avastin was £70,000 per patient year for extension of life.
NHS could not have this price.
NICE said you cannot charge that.
Where is the maths for this price?

Question 7

Require major political and regulatory control

Answer 7

Biologic drugs are often more expensive in US the EU, in 2018 AbbVie agreed to 80% reduction in ceryain EU countries for Humira after introduction of many biosimilars.

Biologic (Drugs that come from living sources)

Question 8

Regulation of drugs is needed

Answer 8

• Vigorous but needs this to promote innovation
• NHS and NICE need to curb influence of patient pressure groups
• Ensures that drugs are available to more people.